Here, we present a precision oncologic approach for localized prostate cancer (PCa) in a 66-year-old man. Overcoming the limitations of conventional MRI in delineating tumor extent and multifocality, preoperative 68Ga-PSMA PET/MRI precisely defined the index lesion and excluded metastases. This diagnostic workflow was directly translated into therapy through PET/MRI-US fusion-guided irreversible electroporation (IRE). The procedure targeted the tumor accurately while sparing surrounding functional anatomy. Significant PSA and phi decline post-IRE confirmed therapeutic efficacy. This case demonstrates that integrating molecularly targeted diagnostics with advanced image-guided focal therapy enables maximal precision in oncologic control.
Xia et al. (Wed,) studied this question.